The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Is There Use for FDG-PET in Prostate Cancer?
Open accessAbstract
The utility of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in prostate cancer depends on the phase of the disease along the natural history of this prevalent malignancy in men. Incidental high FDG uptake in the prostate gland, while rare, should prompt further investigation with at least a measurement of serum prostate specific antigen (PSA) level. While in general FDG uptake level may significantly overlap among normal, benign, and malignant tissues, aggressive primary tumors with Gleason score greater than 7 tend to display high FDG uptake. PET with FDG may be useful in staging of those patients with aggressive primary tumors and can localize the site of disease in a small fraction of men with biochemical failure and negative conventional imaging studies. FDG PET may be quite useful in treatment response assessment and prognostication of patients with castrate-resistant metastatic prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schäfer, J. F., Gatidis, S., Schmidt, H., Gückel, B., Bezrukov, I., Pfannenberg, C. A., Reimold, M., Ebinger, M., Fuchs, J., Claussen, C. D., et al. (2014) · Radiology · doi:10.1148/radiol.14131732 · Cited by 215
Cited by
Molecular imaging in oncology: Current impact and future directions
Rowe, S. P., & Pomper, M. G. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21713 · Cited by 337
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H.-G., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 312
Thang, S. P., Violet, J., Sandhu, S., Iravani, A., Akhurst, T., Kong, G., Ravi Kumar, A., Murphy, D. G., Williams, S. G., Hicks, R. J., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2018.11.007 · Cited by 183
Fonti, R., Conson, M., & Del Vecchio, S. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.07.001 · Cited by 153
Metadata
- Authors
- Jadvar, H.
- Venue
- Seminars in Nuclear Medicine
- Publisher
- Elsevier BV
- Published
- 2016-11
- Volume
- 46
- Issue
- 6
- Pages
- 502-506
- ISSN
- 0001-2998 (ISSN-L)
- OpenAlex
- W2518585392
- Cited by
- 160
- References
- 1
- FWCI
- 11.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is There Use for FDG-PET in Prostate Cancer? https://app.cochat.ai/papers/10.1053/j.semnuclmed.2016.07.004
- The paper
- Jadvar, H. (2016). Is There Use for FDG-PET in Prostate Cancer? Seminars in Nuclear Medicine. https://doi.org/10.1053/j.semnuclmed.2016.07.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.